AIM ImmunoTech Inc. (AIM)
Develops immune-boosting drugs to treat cancers, viral infections, and chronic fatigue.
$0.24-0.06%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-91.4%
The outlook
AIM is trading near its 52-week low, well below both its 50- and 200-day moving averages, signaling a prolonged downtrend. Analyst coverage shows an average price target significantly above the current price, though this contrasts sharply with the stock's bearish overall rating and weak technical positioning.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range1% of the way from its 52-week low to high
Price targetAvg target +2125% vs current price
Analyst price target
~12-month · 2 analysts$5.25average target+2124.6% vs now
Now $0.24
Low $1.50High $9.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$6.5M
52-wk high
$3.58
52-wk low
$0.21
50-day avg
$0.36
200-day avg
$0.98
Trailing P/E
—